ArticleHereditas2025
Optical genome mapping of a complex structural rearrangement family line on chromosome 18.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComplex chromosomal rearrangement (CCR) refers to a structural rearrangement involving at least two chromosomes or a minimum of three breakpoints. CCR may lead to intellectual disability, structural anomalies, infertility, and recurrent miscarriages. Chromosome karyotyping and chromosomal microarray analysis (CMA) are unable to detect complex chromosomal rearrangements. As multiple diagnostic approaches are available in clinical practice for detecting chromosomal structural abnormalities and copy number variations-each with its own advantages and limitations-selecting the appropriate testing method is crucial for effective clinical management. Optical genome mapping (OGM) is an advanced genomic technology that utilizes ultra-long single-molecule analysis to comprehensively detect chromosomal aberrations and structural variants at high resolution. MATERIAL AND
methodsAmniocentesis was performed for a 36-year-old multipara (advanced maternal age), with subsequent comprehensive fetal genetic analysis including chromosome karyotyping, CMA, and OGM. Family members underwent peripheral blood karyotyping and OGM.
resultsThe fetal karyotype derived from amniotic fluid was 46,XN,?ins(18)(q21.2;p11.31p11.2). CMA demonstrated duplications of four segments and a deletion of one segment on chromosome 18. Therefore, OGM was performed on the fetal and family members to further elucidate the chromosomal structure. The fetus has derived CCRs on chromosome 18 of maternal origin. In contrast, both the mother and the second daughter, who carried the identical CCRs, were phenotypically normal.
conclusionOGM is of significant importance in the diagnosis and characterization of CCRs. OGM plays a critical role in diagnosing complex chromosomal rearrangements and has proven to be invaluable in clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.